Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Osteoclast
61%
Tumor
52%
Low-dose Radiation
48%
Overall Survival
45%
Chimeric Antigen Receptor T-cell Therapy
41%
Cell Therapy
36%
Pancreatic Cancer
36%
Macrophages
34%
Radiation Therapy
33%
Glucose Uptake
32%
AKT Inhibitor
32%
Mammalian Target of Rapamycin (mTOR)
32%
Cervical Cancer
32%
Cell Death
32%
Head-and-neck Cancer
32%
Estrogen
32%
Osteoporosis
32%
Dendritic Cells
32%
T Cells
28%
Osteoclast Function
23%
Interleukin-17 (IL-17)
22%
Internal Mammary Lymph Node
22%
CD19
21%
Neoantigen
21%
Salvage Radiotherapy
21%
Antigen Escape
21%
Natural Killer Cells
21%
Breast Cancer
21%
Tumor Immunity
21%
Regional Failure
20%
CAR T-cell Therapy
20%
Receptor Activator of nuclear factor-κB Ligand (RANKL)
19%
Cancer Immunotherapy
19%
Non-Hodgkin Lymphoma
19%
Cytoskeleton
19%
Tumor Targeting
19%
Cell Response
19%
Locoregional Recurrence
18%
Tumor Microenvironment
18%
Solid Tumors
18%
Clinical Experience
18%
Clinical Trials
17%
Re-irradiation
17%
Osteoclastic Bone Resorption
17%
Breast Cancer Patients
17%
Feasibility Outcomes
16%
Immune Cells
16%
Author Names
16%
Cell Salvage
16%
Medicine and Dentistry
Radiation Therapy
95%
Overall Survival
52%
Chimeric Antigen Receptor T-Cell
48%
Breast Cancer
42%
Recurrent Disease
40%
Chimeric Antigen Receptor
37%
Macrophage
37%
Cell Death
33%
Glucose Uptake
32%
Low Drug Dose
32%
Head and Neck Cancer
32%
Cervical Cancer
32%
mTOR Signaling
32%
Protein Kinase B
32%
Diseases
31%
Neoplasm
30%
Chimeric Antigen Receptor T-Cell Immunotherapy
29%
Cell Therapy
27%
Tumor
26%
Malignant Neoplasm
25%
Immunotherapy
23%
Internal Mammary Node
22%
Pancreas Cancer
19%
Cytotoxicity
18%
Stereotactic Body Radiation Therapy
17%
Re-Irradiation
17%
Amyloid Plaque
16%
Metastatic Breast Cancer
16%
Alzheimer's Disease
16%
Metastatic Carcinoma
16%
Immunocompetent Cell
16%
Natural Killer Cell Response
16%
Rectum Carcinoma
16%
Head and Neck Squamous Cell Carcinoma
16%
Adaptive Radiotherapy
16%
Tumor Resistance
16%
Tumor Differentiation
16%
CAR T-cell therapy
16%
Osteoclast
16%
Radiation Necrosis
16%
Intensity Modulated Radiation Therapy
16%
Radioimmunotherapy
16%
Nasopharynx Carcinoma
16%
Pancreas Tumor
16%
Adaptive Radiation
16%
Tumor Cell
15%
Osteoclastogenesis
12%
T Cell
12%
Solid Malignant Neoplasm
12%
Neck
11%
Immunology and Microbiology
Osteoclast
50%
Chimeric Antigen Receptor
45%
Macrophage
37%
Immunotherapy
32%
Low Drug Dose
32%
Dendritic Cell
32%
RANKL
28%
T Cell
24%
Chimeric Antigen Receptor T-Cell
24%
Cytokine
21%
Neoantigen
20%
Overall Survival
18%
CD19
18%
Chimeric Antigen Receptor T-Cell Therapy
18%
Osteoclastogenesis
18%
Cytotoxicity
17%
Cytoskeleton
17%
Interleukin 17
16%
Immunosurveillance
16%
Natural Killer Cell Response
16%
Inflammasome
16%
Neck
16%
T Cell Receptor
16%
Human Immunodeficiency Virus 1
16%
Cancer Immunotherapy
16%
Lineages
16%
Tumor Vaccine
16%
Prostate
16%
Caspase Activation and Recruitment Domain
16%
Osteolysis
13%
Tumor Cell
12%
Squamous Cell
12%
Cyclophosphamide
12%
Macrophage Colony-Stimulating Factor
11%
Oncogene Src
9%
Natural Killer Cell
8%
In Vitro
8%
Tumor Antigen
8%
Vaccine Efficacy
8%
RNA Sequence
8%
TNF related apoptosis inducing ligand
8%
Dendritic Cell Vaccine
8%
Osteoblast
8%
Wild Type
8%
Cetuximab
7%
T-Helper Cell
6%
Cancer Cell
5%
Immune System
5%
Immune Response
5%
Stroma
5%
